You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
UK Biobank hopes cloud-based analytics tools will streamline WGS analysis and open the database to researchers who don't otherwise have access to bioinformatics infrastructure.
Genuity, formerly known as WuXi NextCode, will sequence, analyze, and harmonize samples from Vanderbilt's biobank to inform biomarker and drug discovery.
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
The findings underscore the value of carrying out large-scale human genetic analyses as part of drug target identification and validation efforts.
The GWAS of more than 200,000 Japanese individuals across 42 diseases identified 25 novel loci shared between Japanese and European populations.
The collection of more than 125,000 exomes and 15,000 genomes has enabled an analysis of loss-of-function variants, may help diagnose rare disease, and guide drug development.
British bioinformatics firm PrecisionLife has mined the UK Biobank to identify genetic risk factors for late-stage COVID-19 patients developing sepsis.
Combining questionnaire-derived phenotyping with hospital diagnoses increases the power to tease out genetic associations within biobank data.
The precision medicine center at Colorado's UCHealth expects to add 100,000 participants annually and have 17 drug-gene pairs for pharmacogenomics this year.
The NIGMS repository holds and distributes over 11,700 unique cell lines, as well as more than 6,300 DNA samples, representing over 1,000 heritable diseases.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.